8-甲基-2-苯基-4-喹啉羧酸 | 107027-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 8-甲基-2-苯基-4-喹啉羧酸
• 中文别名: 8-甲基-2-苯基-喹啉-4-羧酸
• 英文名称: 2-phenyl-8-methylquinoline-4-carboxylic acid
• 英文别名: 8-methyl-2-phenylquinoline-4-carboxylic acid；8-methyl-2-phenyl-4-quinolinecarboxylic Acid；8-methyl-2-phenyl-quinoline-4-carboxylic acid；8-Methyl-2-phenyl-chinolin-4-carbonsaeure
• CAS: 107027-34-9
• 化学式: C₁₇H₁₃NO₂
• mdl: MFCD00487551
• 分子量: 263.296
• InChiKey: KNNHBYHNBLIQDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  8-甲基-2-苯基-4-喹啉羧酸 在 氯化亚砜 作用下， 生成 ethyl 8-methyl-2-phenylquinoline-4-carboxylate
  参考文献：
  名称：

  潜在的抗疟药；另外的（2-苯基喹啉基-4）α-哌啶基羰基醇。

  摘要：

  DOI：

  10.1021/ja01216a091
• 作为产物：
  描述：

  丙酮酸 、 邻甲苯胺 在 苯甲醛 作用下， 生成 8-甲基-2-苯基-4-喹啉羧酸
  参考文献：
  名称：

  PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF

  摘要：

  提供了一种工业上优势合成喹啉羧酰胺衍生物或其盐的生产中间体的方法。本发明提供了一种制备喹啉羧酸衍生物的方法，其化学式为（4）或其盐，包括在三氟化硼-四氢呋喃复合物或三氟化硼-二乙醚复合物的存在下，用化学式（1）的苯胺与化学式（2）的醛反应，然后用化学式（3）的α-酮酸反应所得化合物，其中R1、R2、R3和R4相同或不同，每个代表氢原子、卤素原子、低级烷基或类似物，R5代表氢原子、低级烷基或类似物，R6代表氢原子、低级烷基或类似物。

  公开号：

  US20220169640A1

文献信息

• Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide
  作者：Chen Liao、Yan Liu、Chunxia Liu、Jiaqi Zhou、Huilan Li、Nasi Wang、Jieming Li、Taiyu Liu、Hesham Ghaleb、Wenlong Huang、Hai Qian

  DOI：10.1016/j.bmc.2017.12.048

  日期：2018.2

  constructed on a phenylquinoline platform that evolved from Cinchophen lead. This design composes three sections: a phenylquinoline headgroup attached to an aliphatic carboxamides, which is tethered at a phenyl tail group. Optimization of this design led to the identification of 37, comprising a pyrrolidine linker and a trifluoromethyl–phenyl tail. In the TRPV1 functional assay, using cells expressed hTRPV1

  本文报道的是设计，合成和药理学表征的一类在从喹古芬铅进化而来的苯基喹啉平台上构建的TRPV1拮抗剂。该设计包括三个部分：连接到脂族羧酰胺的苯基喹啉头基，该端基被束缚在苯基尾基上。该设计的优化导致鉴定出37个，其中包括一个吡咯烷连接子和一个三氟甲基-苯基尾巴。在TRPV1功能测定中，使用表达hTRPV1的细胞，有37种拮抗辣椒素诱导的Ca 2+内流，IC 50值为10.2 nM。在完整的小鼠镇痛模型中，37在不同的疼痛模型中，与阳性对照BCTC相比，它们显示出更好的抗伤害感受活性。所有这些结果表明，可以考虑将37种药物作为抗伤害性药物进一步开发的主要候选药物。
• Quinoline-4-carbonylguanidine derivatives, process for producing the
  申请人：Mitsui Toatsu Chemicals, Inc.

  公开号：US05627193A1

  公开（公告）日：1997-05-06

  The present invention relates to quinoline-4-carbonylguanidine derivative represented by formula (1) ##STR1## and pharmaceutically acceptable salt thereof, a process for producing the same, and a Na.sup.+ /H.sup.+ exchanger inhibitor containing the compound as an active ingredient. The compounds of the present invention are useful as an agent for treating or preventing various diseases by hyperfunction of the Na.sup.+ /H.sup.+ exchanger and as a diagnostic agent for these diseases.

  本发明涉及由式（1）所代表的喹啉-4-羰基胍衍生物及其药学上可接受的盐，制备该化合物的方法，以及含有该化合物作为活性成分的Na.sup.+ /H.sup.+交换抑制剂。本发明的化合物可用作治疗或预防由Na.sup.+ /H.sup.+交换器的高功能引起的各种疾病的药剂，以及用于这些疾病的诊断剂。
• Substituted quinoline derivatives and pharmaceutical compositions thereof
  申请人：Development Finance Corporation of New Zeland

  公开号：US04904659A1

  公开（公告）日：1990-02-27

  The novel class of substituted quinolines represented by the general formula (I): ##STR1## where each of R.sub.1 and R.sub.2 separately represents H or up to three of the groups lower alkyl, halogen, CF.sub.3, CN, SO.sub.2 CH.sub.3, NO.sub.2, OH, NH.sub.2, NHSO.sub.2 R.sub.3, NHCOOR.sub.3, OR.sub.3, SR.sub.3, NHR.sub.3 or NR.sub.3 R.sub.3 (where R.sub.3 is lower alkyl optionally substituted with hydroxy, amino or ether functions), and each of R.sub.1 and R.sub.2 may additionally separately represent the substitution of an aza (--N.dbd.) group for one or two of the methine (--CH.dbd.) groups in each of the carbocyclic rings, and R.sub.1 may also represent, at positions 2', 3' or 4' only, a phenyl ring optionally further substituted with lower alkyl, halogen, CF.sub.3, CN, SO.sub.2 CH.sub.3, NO.sub.2, OH, NH.sub.2, NHCOR.sub.3, NHCOOR.sub.3, OR.sub.3, SR.sub.3, NHR.sub.3 or NR.sub.3 R.sub.3 (where R.sub.3 is lower alkyl optionally substituted with hydroxy, amino or ether functions); Y represents C(NH)NH.sub.2, NHC(NH)NH.sub.2 or NR.sub.4 R.sub.5, where each of R.sub.4 and R.sub.5 is H or lower alkyl optionally substituted with hydroxy, amino or ether functions, or R.sub.4 and R.sub.5 together with the nitrogen atom form a heterocyclic ring; and n is from 2 to 6; and the acid addition salts and 1-N-oxides thereof, possess antibacterial and antitumor properties.

  被一般式(I)所代表的取代喹啉新类化合物，其中R.sub.1和R.sub.2各自代表H或最多三个低碳链烷基、卤素、CF.sub.3、CN、SO.sub.2 CH.sub.3、NO.sub.2、OH、NH.sub.2、NHSO.sub.2 R.sub.3、NHCOOR.sub.3、OR.sub.3、SR.sub.3、NHR.sub.3或NR.sub.3 R.sub.3（其中R.sub.3是低碳链烷基，可选地取代羟基、氨基或醚基功能），且R.sub.1和R.sub.2各自还可以分别代表在每个碳环中的一个或两个亚胺（--N.dbd.）基取代一个或两个亚甲烷（--CH.dbd.）基，且R.sub.1还可以代表仅在2'、3'或4'位置的苯环，该苯环可选择性地进一步取代为低碳链烷基、卤素、CF.sub.3、CN、SO.sub.2 CH.sub.3、NO.sub.2、OH、NH.sub.2、NHCOR.sub.3、NHCOOR.sub.3、OR.sub.3、SR.sub.3、NHR.sub.3或NR.sub.3 R.sub.3（其中R.sub.3是低碳链烷基，可选地取代羟基、氨基或醚基功能）；Y代表C(NH)NH.sub.2、NHC(NH)NH.sub.2或NR.sub.4 R.sub.5，其中R.sub.4和R.sub.5各自是H或低碳链烷基，可选择性地取代羟基、氨基或醚基功能，或者R.sub.4和R.sub.5与氮原子一起形成杂环；n为2至6；以及其酸盐和1-N-氧化物具有抗菌和抗肿瘤性能。
• N-type calcium channel antagonists for the treatment of pain
  申请人：——

  公开号：US20040053964A1

  公开（公告）日：2004-03-18

  Compounds useful for the treatment of pain in accord with the following structural diagram, 1 wherein R 1 , R 2 , R 3 , R 4 and R 5 are any of a number of groups as defined in the specification, A and D are as defined in the specification, and pharmaceutical compositions and methods of treatment utilising such compounds.

  以下结构图所示的化合物可用于治疗疼痛，其中R1、R2、R3、R4和R5是规范中定义的许多基团中的任何一个，A和D如规范中所定义，以及利用这些化合物的制药组合物和治疗方法。
• Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase
  作者：Andrew N. Boa、Shane P. Canavan、Paul R. Hirst、Christopher Ramsey、Andrew M.W. Stead、Glenn A. McConkey

  DOI：10.1016/j.bmc.2005.01.017

  日期：2005.3

  A series of 2-phenyl quinoline-4-carboxylic acid derivatives related to brequinar, an inhibitor of human dihydroorotate dehydrogenase (DHODH), has been prepared and evaluated as inhibitors of DHODH from the malaria parasite Plasmodium falciparum. Brequinar was essentially inactive against PfDHODH (IC50 880 mu M) whereas several members of the series inhibited PfDHODH. Unexpectedly, replacement of the carboxylic acid required for brequinar to inhibit hDHODH was not essential in the diisopropylamides that inhibited PfDHODH. (c) 2005 Elsevier Ltd. All rights reserved.